An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2017-11-27
• Target enrollment: 0
• Participant gender: All

Summary

This prospective observational study will evaluate the safety and efficacy of first-line rituximab maintenance therapy in participants with follicular non-Hodgkin's lymphoma. Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will be followed for a maximum of 3 years or until disease progression occurs.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Histological diagnosis of follicular non-Hodgkin's lymphoma

• Complete or partial response to first-line induction therapy with chemotherapy with rituximab

• Participants about to receive first-line rituximab maintenance treatment for follicular non-Hodgkin's lymphoma according to the local label

Exclusion Criteria:

• Pregnant or lactating women

• Receipt of an investigational drug within 30 days prior to initiation of observational drug

• Any medical or psychological alteration that, to criterion of the investigator, can jeopardize the capacity of the participant to grant informed consent

• Central nervous system involvement

• Hepatitis B or C virus infection or human immunodeficiency virus infection